The indictment of Theranos founder Elizabeth Holmes, and the barrage of shocking details about her company unearthed in John Carreyrou's best-selling chronicle of the Theranos saga, Bad Blood, could give nightmares to people who invest in biotech firms that have not yet listed their shares on public markets. But if fundraising in healthcare this year is any indication, that's not happening.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,